|
Dose-effect relationships of drug combinations in human androgen-independent prostate cancer cell line LNCaP C4-2B: Gefitinib (Ge), Lapatinib (La) and Cyclopamine (Cy). |
||||||||
| Treatment |
Parameters |
CI value at |
Range |
Significance |
||||
|
|
||||||||
| Dm |
m |
r |
ED50 |
ED75 |
ED90 |
|||
|
|
||||||||
| Ge+Cy (12:1) |
9.5 |
0.44 |
0.94 |
0.22 |
0.06 |
0.02 |
0.1–0.3 |
strong synergism |
| La+Cy (7:1) |
5.8 |
0.44 |
0.94 |
0.14 |
0.06 |
0.03 |
0.1–0.3 |
strong synergism |
Shaw and Prowse Cancer Cell International 2008 8:3 doi:10.1186/1475-2867-8-3 |
||||||||